Assistance Publique Hopitaux De Marseille
Verified
Marseille, France
Not recruiting
Study on Dapagliflozin and Balcinrenone for Patients Over 50 with Stage 3 Chronic Kidney Disease
Verified siteRegistered drug
Clinical Trials Concierge
Prefer not to search? Our Concierge searches the trials for you.
What is this trial about?
A plain-language summary of the goals, design and what participants do
This clinical trial is focused on studying the effects of certain medications on people with chronic kidney disease, specifically those in stage 3. The study involves two main medications: dapagliflozin and balcinrenone. Dapagliflozin is a type of medication known as an SGLT2 inhibitor, which helps the kidneys remove glucose from the body. Balcinrenone, also known by its code name AZD9977, is a synthetic small molecule that is being tested for its potential benefits in kidney disease. Some participants will receive a placebo, which is a substance with no active medication, to compare the effects of the actual drugs.
The purpose of the study is to explore how these medications, either alone or in combination, affect the body's handling of fluids and electrolytes, as well as energy metabolism. Participants in the study will be over 50 years old and will have their kidney function monitored. The study will last for a period of up to 32 weeks, during which participants will take the medications orally in the form of tablets or capsules. The researchers aim to see if balcinrenone can maintain the beneficial effects of dapagliflozin on kidney function, particularly in terms of glucose excretion.
Throughout the study, various health markers will be measured, such as changes in urine glucose levels, muscle water content, and other indicators of kidney and metabolic health. These measurements will help determine the effectiveness and safety of the treatments. The study will also monitor any side effects that may occur during the treatment period. By the end of the study, the researchers hope to gain a better understanding of how these medications can help manage chronic kidney disease and improve patient outcomes.
The research process
The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.
Who can join the trial?
10 criteria
- Patients must be **over 50 years old**.
- Must have a **diagnosis of chronic kidney disease** with a specific kidney function level, known as **eGFR**, between 30 and 60.
- For patients in Germany, **potassium levels** in the blood should be between 3.5 and 5.0, or within normal ranges if provided, checked within 2 weeks before starting the study.
- For patients in France, **potassium levels** in the blood should be between 3.5 and 5.0, checked within 2 weeks before starting the study.
- **Sodium levels** in the blood should be within normal reference values within 2 weeks before starting the study.
- If patients have **type 2 diabetes**, they can be on certain diabetes medications like metformin, sulphonylureas, or DPP4 inhibitors, alone or in combination, with or without insulin. If used, the dose should be stable for 12 weeks before starting the study.
- No changes in other treatments for at least 3 weeks before starting the study.
- **Body mass index (BMI)** should be less than 40. BMI is a measure of body fat based on height and weight.
- For women who can have children, a **negative pregnancy test** is required, and they must agree to use effective birth control.
- Participants must be willing to join the study and able to provide **signed informed consent**, which means they understand and agree to follow the study's rules and requirements.
Who cannot join the trial?
5 criteria
- Patients with **Stage 3 chronic kidney disease** cannot participate. This means their kidneys are not working as well as they should, but they are not in the most severe stage.
- Patients who are not within the specified age range for the study cannot participate. The study is looking for people in certain age groups.
- Patients who are not part of the specified clinical trial groups cannot participate. This means the study is looking for people with certain characteristics or conditions.
- Both **male and female** patients can participate, but if someone does not fit the gender criteria, they cannot join.
- Patients who are considered part of a **vulnerable population** cannot participate. This means people who might need extra protection or care are not included in the study.
Clinical Trials Concierge
Prefer not to search? Our Concierge searches the trials for you.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
Verified sites
All sites with verified contact details – recruitment status may not be available; ask directly
Klinikum Nuernberg
Verified
Nürnberg, Germany
Trial locations
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
Not recruitingNot finding your country?
Not sure what to do next?
Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
Investigated drugs
Dapagliflozin
is a medication used to help control blood sugar levels in people with chronic kidney disease. It works by helping the kidneys remove glucose from the bloodstream, which can also aid in managing body fluid and electrolyte balance.
Balcinrenone
is a medication being studied for its potential to support kidney function. In this trial, it is being tested to see if it can enhance the effects of dapagliflozin, particularly in maintaining the beneficial increase in glucose excretion by the kidneys.
What is already known about the treatment
Dapagliflozin
Dapagliflozin is administered orally in tablet form and is currently being studied for its effects on chronic kidney disease. It is widely recognized in medical literature as a medication primarily used to manage type 2 diabetes and heart failure. The main therapeutic indication in this trial is to enhance glucose excretion in the kidneys. At the molecular level, dapagliflozin works by inhibiting the sodium-glucose co-transporter 2 (SGLT2) in the kidneys, which reduces glucose reabsorption and increases glucose excretion in urine. It is classified as an SGLT2 inhibitor.
Balcinrenone
Balcinrenone is administered orally and is under investigation for its potential benefits in chronic kidney disease. It is not yet widely established in medical literature, as it is still in the clinical trial phase. The primary therapeutic indication in this study is to preserve the beneficial effects of dapagliflozin on renal glucose excretion. Balcinrenone acts at the molecular level by modulating mineralocorticoid receptor activity, which may help in managing fluid and electrolyte balance. It is classified as a mineralocorticoid receptor antagonist.
Investigated diseases
Stage 3 Chronic Kidney Disease – This condition is characterized by a moderate decrease in kidney function, where the kidneys are not filtering blood as well as they should. It is typically identified by a reduction in the glomerular filtration rate (GFR) to between 30 and 59 mL/min/1.73 m². As the disease progresses, waste products can build up in the blood, leading to symptoms such as fatigue, swelling in the legs, and changes in urination patterns. Patients may also experience high blood pressure and bone health issues due to imbalances in minerals and hormones. The progression of the disease can vary, and it may remain stable for some time or gradually worsen. Regular monitoring and lifestyle adjustments are often necessary to manage the condition.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IITrial ID2024-516032-10-00Protocol codeCT114-2022-01Estimated enrolment150 patientsSponsorKlinikum Nuernberg
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?